HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease.
We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
Andrew Griffiths, PhD
Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI)
David Weitz, PhD
Mallinckrodt Professor of Physics & Applied Physics and Professor of Systems Biology at Harvard University
Bradley Bernstein, MD, PhD
Professor of Pathology at the Massachusetts General Hospital and Harvard Medical School
Jérôme Bibette, PhD
Professor of Soft Matter Physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)
Robert Nicol, PhD
Director of the Technology Labs at the Broad Institute of MIT and Harvard
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand single-cell analytics and accelerate commercialization. All of our collaborations are architected for speed and driven by our scientific strategy.